In its interim report on economic outlook, OECD said: “Activity moved above pre-pandemic levels in China, India, and Turkey, helped by strong fiscal and quasi-fiscal measures and a recovery in manufacturing and construction.”
It, however, pegged economic growth rate to come down to 5.4 per cent in 2022-23, which would be higher by 0.6 percentage points than its earlier estimates. That year, India would share its fastest-growing large economy tag with Indonesia, according to the OECD. This meant that economic rebound in 2021-22 would largely be a statistical illusion due to low base effect.
The Indian economy was officially projected to decline by 8 per cent in the current fiscal year. However, OECD believes that contraction would be less steep at 7.4 per cent. In the report, titled “Strengthening the recovery: The need for speed”, OECD said fiscal measures announced in India and a few other countries would help growth in 2021-22 as well.
“Additional discretionary fiscal measures announced in several countries during the past three months will add to the overall support, including in the US, Japan, Germany, Canada, and India,” the report said.
As businesses were almost shut in April last year due to the countrywide lockdown, announced to tackle the pandemic, Finance Minister Nirmala Sitharaman announced the first package in March. She followed these up with three more.
The report, however, cautioned that higher commodity prices will also raise inflation in net commodity importers, such as India and Turkey, relative to commodity exporters.
OECD pegged global economic growth rate at 5.6 per cent in the current calendar year, 1.4 percentage-point higher than its earlier estimate. It projected the world economy to grow by less rate at four per cent in 2022, but still 0.3 percentage point higher than its earlier projection. The global economy had contracted 3.4 per cent last year, according to it.
The report said the advanced economies, as well as vaccine suppliers such as China, India, and Russia also face potential risks from the spread of new mutations and the re-imposition of containment measures from the latter half of 2021, but face less near-term uncertainty about vaccine production and deployment, which is likely to be completed during 2021.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)